Rick Klausner’s crew of T cell specialists wraps $425M IPO, hitting Nasdaq alongside Verve, Molecular Partners

It’s harvest day for a pair of biotech startups with lofty goals to break new ground in cancer and coronary heart disease — and their high-profile founders.

Rick Klausner’s Lyell Immunopharma and Sek Kathiresan’s Verve Therapeutics have both priced their IPOs, raising $425 million and $266.7 million, respectively. Neither are...

Click to view original post